Find a Clinical Trial

Find a Clinical Trial

Use the abbreviation for your state (ie. FL, TX, NV)
Search by practice name, trial titles, indicators and specific disease types.

Lung Cancer

Clinical Trial at: Florida Cancer Affiliates - Ocala

CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

  • Details

ClinicalTrials.gov ID: NCT02574078
Diagnosis Type: NSCLC
USOR Number: 14158

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Neuroendocrine Tumors

Clinical Trial at: Florida Cancer Affiliates - Ocala

A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

  • Details

ClinicalTrials.gov ID: NCT02683941
Diagnosis Type: NA
USOR Number: 15079

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Mesothelioma

Clinical Trial at: Florida Cancer Affiliates - Ocala

Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93)

  • Details

ClinicalTrials.gov ID: NCT01907100
Diagnosis Type: NA
USOR Number: 15175

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Lung Cancer

Clinical Trial at: Florida Cancer Affiliates - Ocala

A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks(CheckMate 384- CA209384)

  • Details

ClinicalTrials.gov ID: NCT02713867
Diagnosis Type: NA
USOR Number: 15203

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Florida Cancer Affiliates - Ocala

A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)

  • Details

ClinicalTrials.gov ID: NCT02872714
Diagnosis Type: NA
USOR Number: 15228

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Biliary Cancer

Clinical Trial at: Florida Cancer Affiliates - Ocala

A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

  • Details

ClinicalTrials.gov ID: NCT02924376
Diagnosis Type: NA
USOR Number: 16066

  • Practice Details

433 SW 10th Street
Ocala, Florida 34471
111.28 mi. away
P: (352) 732-4032

More Details View Practice Page

Pages